PhaseBio Pharmaceuticals Inc logo

PhaseBio Pharmaceuticals Inc

$ 0.05 -0.0001 (-0.22%) 03:56 PM EST
P/E:
At Loss
P/B:
0
Market Cap:
$ 2.24M
Enterprise V:
$ -483.00K
Volume:
951.48K
Avg Vol (2M):
2.49M
Also Trade In:
Volume:
951.48K
Market Cap $:
2.24M
PE Ratio:
At Loss
Avg Vol (2-Month):
2.49M
Enterprise Value $:
-483.00K
PB Ratio:
0

Business Description

Description
PhaseBio Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies to treat orphan diseases, with an initial focus on cardiopulmonary indications. The lead product candidate of the company is PB2452, which is a novel reversal agent for the antiplatelet drug ticagrelor, used for the treatment of patients experiencing major bleeding or those who require urgent surgery. It is also developing PB1046 which is a fusion protein for the treatment of pulmonary arterial hypertension. The company is also developing its preclinical product candidate, PB6440, for treatment-resistant hypertension.

Financial Strength

Name Current Vs Industry Vs History
Cash-To-Debt 1.45
Equity-to-Asset -5.3
Debt-to-Equity -0.05
Debt-to-EBITDA -0.05
Piotroski F-Score 3/9
0
1
2
3
4
5
6
7
8
9
Altman Z-Score -42.38
Distress
Grey
Safe
Beneish M-Score -16.33
Manipulator
Not Manipulator
WACC vs ROIC
WACC
ROIC

Momentum Rank

Name Current Vs Industry Vs History
5-Day RSI 29.28
9-Day RSI 32.46
14-Day RSI 30.76
6-1 Month Momentum % -89.24
12-1 Month Momentum % -96.59

Liquidity Ratio

Name Current Vs Industry Vs History
Current Ratio 0.47
Quick Ratio 0.47
Cash Ratio 0.32

Dividend & Buy Back

Name Current Vs Industry Vs History
3-Year Average Share Buyback Ratio -25.3

Profitability Rank

Name Current Vs Industry Vs History
Operating Margin % -12738.63
Net Margin % -12572.13
ROA % -171.55
ROIC % -473.17
ROC (Joel Greenblatt) % -883.99
ROCE % -271.94

GF Value Rank

Name Current Vs Industry Vs History
PS Ratio 2.62
EV-to-Revenue -0.59
EV-to-Forward-Revenue 0.32